01How the compounded market was built — and why it's closing

Federal law lets 503A compounding pharmacies and 503B outsourcing facilities make copies of an FDA-approved drug when that drug is on the FDA's shortage list. Semaglutide and tirzepatide landed on the shortage list in 2022 as demand exploded after the Wegovy (2021) and Zepbound (2023) approvals. That shortage window — not a loophole — is what allowed compounded GLP-1s to reach roughly a third of US supply at peak, at $100–$300/month versus $1,000+ for brand.

When the FDA confirmed manufacturers could meet demand, it removed the drugs from the shortage list. That single administrative act removed the legal basis for routine compounding.

02The timeline that matters

Sources: FDA drug shortage determinations and compounding policy updates (2024–2026); Federal Register docket on the 503B bulks list proposal.

03What is still legal — exactly

Two narrow paths remain. First, patient-specific 503A compounding: a state-licensed pharmacy may compound for an individual patient under a valid prescription if the compounded drug is not "essentially a copy" of a commercially available product — meaning the prescriber has documented a clinical need for a specific change (for example, a different formulation or the removal of an inactive ingredient a patient cannot tolerate). Second, FDA's "essentially a copy" prohibition still allows limited compounding when a documented medical need justifies a modification. Both paths require a real prescriber, a real evaluation, and documentation. Neither permits mass production of standard-dose copies.

Everything sold as "research use only," anything without a named US-licensed pharmacy and prescriber, and any product imported from overseas without oversight is outside the law and is exactly where the FDA's adverse-event reports and counterfeit warnings concentrate.

04The safety record behind the crackdown

As of early 2025, the FDA had received more than 455 adverse-event reports tied to compounded semaglutide and more than 320 tied to compounded tirzepatide, many involving dosing errors from patients self-measuring from multi-dose vials — some requiring hospitalization. Counterfeit products sold online without prescriptions compounded the problem. This is the patient-safety rationale the agency cites alongside the resolved-shortage legal basis. If you are considering any compounded GLP-1, read our provider verification checklist first.

05What it means for your cost

As compounded access narrows, the brand-name cash-pay picture has shifted to fill the gap. Manufacturer self-pay programs dropped sharply: Zepbound single-dose vials via LillyDirect now run roughly $349–$499, and Novo Nordisk's NovoCare/oral routes start around $149–$499 for some doses — far below the $1,000+ retail list prices. Compounded programs from compliant 503A providers still tend to be lower for now, but the gap is closing and the legal ground is shifting. See the full cost comparison and our tirzepatide and semaglutide price records.

Not legal advice. Regulatory status is changing rapidly and varies by state and by individual clinical circumstances. Confirm current status with a licensed clinician and your state board of pharmacy before making any decision.